Dalargin
Also known as: Dalargina, Dalar
Molecular Identifiers
Overview
Synthetic hexapeptide analog of leu-enkephalin, with a molecular weight of approximately 726.81 Da. Developed in the Soviet Union as a gastroprotective agent, it primarily acts on delta-opioid receptors. Widely used in Russian medicine for the treatment of gastrointestinal ulcers and promotion of tissue healing.
Dalargin is mainly used as a gastroprotective and mucosal healing agent: it reduces gastric acid secretion, modulates mucosal microcirculation, and favors tissue regeneration in gastric and duodenal ulcers. It has also been investigated for cardiac protection, acute pancreatitis, and wound healing. Because it preferentially acts on peripheral delta-opioid receptors, it maintains a weak analgesic profile and limited central opioid effects.
It is registered as a medicine in Russia and CIS countries, where it has been used clinically for decades in hospital settings. Outside that context it has no approval from the FDA, EMA, or ANVISA, and access depends on compounding pharmacies or import. Typical administration is subcutaneous or intramuscular, in short 10-20 day cycles.
It was developed in the Soviet Union as a synthetic analog of leu-enkephalin, with the introduction of D-alanine at position 2 to resist peptidase degradation. Most publications are in Russian-language literature, and robust international clinical trials are still scarce.
Tyr-D-Ala-Gly-Phe-Leu-Arg Contains D-amino acids
Half-life
~15-30 minutes
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Selective delta-opioid receptor (DOR) agonism
- Gastroprotection via reduction of gastric acid secretion
- Anti-ulcer effect with gastrointestinal mucosal protection
- Promotion of healing and tissue regeneration
- Modulation of microcirculation in the gastric mucosa
- Cytoprotective effect on mucosal cells
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 1-2 mg per injection (subcutaneous or intramuscular) |
| Frequency | 1-2 times daily |
| Timing | Morning and/or evening, preferably fasting |
| Duration | 10-20 days |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Drowsiness
- Dizziness
- Mild nausea
- Bradycardia (high doses)
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of Dalargin found in the research market:
Reconstitution
- Diluent: Bacteriostatic water or sterile saline solution
- Volume: 1-2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved — never shake
- Solution should be clear and colorless
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 14 days)
- Protect from direct light
- Do not freeze after reconstitution
- Discard if turbidity occurs
Scientific Studies
Published studies on Dalargin.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
Bronchogen
1-2 capsules orally (0.2 g per capsule, containing AKS-B peptide complex) · 1-2 times daily, with meals
Cardiogen
Chonluten
1-2 capsules orally (0.2 g per capsule, containing bronchial tissue peptide complex) · 1-2 times daily, with meals
Crystagen
1-2 capsules orally (0.2 g per capsule, containing AKS-6 peptide complex) · 1-2 times daily, before meals